angelinipharma.comCrawled Nov 9, 2026
Angelini Pharma supports independent clinical and non-clinical research by providing funding or investigational products.
The page requires applicants to download and read specified documents before submitting their application.
Following its ByMyEpilepside global communications campaign, Angelini Pharma is adding a new chapter to the epilepsy story with the launch of the short film Lightning.
Angelini products are commercialised worldwide thanks to licensing out and export agreements with more than 40 partners.
Angelini Pharma seeks new solutions and invests in research to improve the management and quality of life for patients with mental health and neurological disorders.
Angelini Pharma cares for people’s health by putting the needs and wants of patients and consumers at the centre.
The page examines epilepsy through data, scientific knowledge, and real-world perspectives on symptoms, care, daily life, brain health, and unmet needs.
The burden of mental health conditions is on the rise globally. Only in Europe, diverse forms of mental disorders affect nearly 40% of the total population annually, leading to premature mortality and impacting functioning and quality of life of both patients and their families.
With healthcare policies, medical guidelines and not surprisingly prescriptions increasingly under scrutiny from both Health Authorities and budget holders, the goals for healthcare professional communications are rapidly changing.
Brussels, October 9th, 2019: Angelini Pharma’s international Public Affairs initiative “Headway2020 : A new roadmap in Mental Health” goes public ahead of the 27th World Mental Health Day at the European Parliament.
The Amuchina plant in Casella produces the disinfectant Amuchina, employing 38 people across 17,000 square meters.
Media Resources of Angelini Pharma website
When I Grow Up is a series of short video interviews through which Angeliner explain how they came to work in the pharmaceutical world and what’s their role inside the company.
The information on this page concerns the clinical studies conducted by Angelini Pharma and is not for promotional purposes.
The page presents Angelini Pharma’s key financial data.
Angelini Pharma collaborates with universities and institutions to share knowledge, laboratories, and best practices in pharmaceutical innovation.
With five strategically located production facilities, Angelini Pharma has solidified its position as a global player in the pharmaceutical industry.
Welcome to the official Angelini Pharma website
in accordance with Regulation (EU) 2024/1689 (“EU AI Act”) and the Italian Law no. 132/2025 (“Italian AI Law”)
The page contains the clinical studies privacy notices.
The page contains the privacy notice for pharmacovigilance.
The page contains the social media privacy notice.
Angelini Pharma’s Chief Medical Officer, Agnese Cattaneo, presents at the **European Epilepsy Summit 2026** in Brussels. She participates in the **Leadership Panel** on integrating epilepsy into broader brain health strategies. The event, organized by the **International Bureau for Epilepsy (IBE)**, focuses on translating research into policy and clinical action.
Nov 2026angelinipharma.comNews article
Angelini Pharma presents research at the **39th ECNP Congress** to advance **personalized depression treatment** based on scientific consensus. The event, held in Munich, aligns with **World Mental Health Day (October 10)** and gathers global experts to explore neuroscience breakthroughs. The focus centers on translating research into tailored patient care strategies.
Oct 2026angelinipharma.comNews article
Angelini Pharma secures the **EcoVadis Gold Medal**, placing it among the top 5% of companies globally for sustainability performance. The recognition highlights advancements in the company’s environmental, social, and governance (ESG) practices. EcoVadis evaluates criteria such as supply chain transparency, ethical business conduct, and carbon footprint reduction.
Sep 2026angelinipharma.comNews article
Angelini Pharma participates in **EEC 2026**, the European Epilepsy Congress, to present advancements in epilepsy treatment and care. The event, held in Athens from **September 5–9, 2026**, unites clinicians, researchers, and professionals to explore new therapeutic approaches. The company highlights innovations aimed at improving seizure management and holistic patient support.
Sep 2026angelinipharma.comNews article
